| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Angela Jiang | |
| Jillian Wang | |||
| Malav Joshi | |||
| John Byron Christoforidis | |||
| P2860 | cites work | Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study | Q82509003 |
| Favorable response to high-dose infliximab for refractory childhood uveitis | Q82869656 | ||
| Successful treatment of severe nodular scleritis with adalimumab | Q82898534 | ||
| Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon's injection | Q83395978 | ||
| Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis | Q83433979 | ||
| Infliximab therapy for refractory uveitis: 2-year results of a prospective trial | Q84022834 | ||
| Therapy: Behçet uveitis: good results for IFN-alpha-2a | Q84727765 | ||
| Leflunomide and malononitriloamides | Q94447042 | ||
| Adverse effects of biologics: a network meta-analysis and Cochrane overview | Q24234197 | ||
| Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study | Q24630541 | ||
| Effects of mycophenolate mofetil on key pattern of coronary restenosis: a cascade of in vitro and ex vivo models | Q24810773 | ||
| Structural basis of immunosuppression by the therapeutic antibody daclizumab | Q27664283 | ||
| Mechanism of action for leflunomide in rheumatoid arthritis | Q28140432 | ||
| Tocilizumab: a review of its use in the management of rheumatoid arthritis | Q28241360 | ||
| Daclizumab for treatment of birdshot chorioretinopathy | Q28268417 | ||
| Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes | Q28277749 | ||
| A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab | Q28282330 | ||
| Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety | Q33328963 | ||
| Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment | Q33346179 | ||
| Systemic treatment of vitreous inflammation. | Q38048774 | ||
| Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies. | Q38087452 | ||
| Cyclophosphamide-induced remissions in advanced polyarteritis nodosa | Q39190353 | ||
| The therapeutic use of azathioprine in renal transplantation | Q39691682 | ||
| Toxicity of low dose methotrexate in rheumatoid arthritis. | Q39841838 | ||
| Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial | Q42276574 | ||
| Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). | Q42939553 | ||
| Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. | Q43048775 | ||
| Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis | Q43192300 | ||
| Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience | Q43728566 | ||
| Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group | Q43760451 | ||
| Short-term chlorambucil for refractory uveitis in Behcet's disease | Q43949310 | ||
| Intravenous daclizumab for recalcitrant ocular inflammatory disease | Q44493607 | ||
| Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. | Q44881570 | ||
| Leflunomide for chronic sarcoidosis | Q44884377 | ||
| Granulomatous sclerouveitis. Regression of ocular lesions with cyclophosphamide and prednisone | Q45177640 | ||
| Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report | Q45180236 | ||
| The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules | Q45216641 | ||
| Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis | Q45261256 | ||
| Tocilizumab treatment for refractory uveitis-related cystoid macular edema. | Q45903627 | ||
| Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. | Q45998968 | ||
| Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. | Q46789756 | ||
| Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial | Q47778828 | ||
| Adalimumab for juvenile idiopathic arthritis-associated uveitis. | Q48625167 | ||
| Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. | Q48685987 | ||
| Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. | Q50160651 | ||
| A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. | Q51439320 | ||
| Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. | Q53787487 | ||
| Catatonic mutism after liver transplant rapidly reversed with lorazepam. | Q55043851 | ||
| Immunosuppressive Therapy for Ocular Mucous Membrane Pemphigoid | Q59305616 | ||
| Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease | Q63214371 | ||
| Triple Agent Immunosuppression in Serpiginous Choroiditis | Q67935522 | ||
| Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine | Q68402081 | ||
| Cyclophosphamide therapy of Behcet's disease | Q68433835 | ||
| Scleritis in relapsing polychondritis. Response to therapy | Q68877903 | ||
| Immunosuppressive therapy for progressive ocular cicatricial pemphigoid | Q70249115 | ||
| Effect of Cyclophosphamide upon the Immune Response in Wegener's Granulomatosis | Q70620742 | ||
| Chlorambucil in Behçet's disease. A reappraisal | Q71080244 | ||
| Long-term cyclophosphamide therapy in rheumatoid arthritis | Q72046682 | ||
| Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy | Q72438115 | ||
| Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial | Q73775013 | ||
| Cataract surgery in children with chronic uveitis | Q73977608 | ||
| Immunosuppressive agents: recent developments in molecular action and clinical application | Q74686279 | ||
| Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine | Q77319364 | ||
| Multifocal choroiditis and panuveitis: immunomodulatory therapy | Q77590201 | ||
| Adalimumab therapy for childhood uveitis | Q79163616 | ||
| Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study | Q80263649 | ||
| Adalimumab therapy for refractory uveitis: a pilot study | Q81267829 | ||
| Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report | Q82382077 | ||
| Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review | Q33457485 | ||
| Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities | Q33625396 | ||
| Treatment strategies in patients with posterior uveitis | Q33903847 | ||
| Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. | Q33920749 | ||
| High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis | Q34070773 | ||
| Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study | Q34122642 | ||
| Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil | Q34322123 | ||
| Long-term daclizumab therapy in relapsing-remitting multiple sclerosis | Q34409257 | ||
| A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis | Q34709640 | ||
| Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis | Q34756444 | ||
| Calcineurin inhibitor nephrotoxicity | Q34945314 | ||
| Molecular differences in anticytokine therapies | Q35127581 | ||
| The efficacy of sirolimus in the treatment of patients with refractory uveitis | Q35593216 | ||
| Interferon as a treatment for uveitis associated with multiple sclerosis | Q35593835 | ||
| The use of interferon alpha in Behçet disease: review of the literature | Q35744081 | ||
| The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. | Q35788464 | ||
| Immunomodulatory medications in uveitis | Q35813809 | ||
| Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies | Q35895953 | ||
| Immunosuppression for posterior uveitis | Q36012275 | ||
| Biological response modifier therapy for refractory childhood uveitis | Q36025876 | ||
| Infliximab in chronic ocular inflammation | Q36037311 | ||
| Management of sight-threatening uveitis: new therapeutic options. | Q36055455 | ||
| Adalimumab for sight-threatening uveitis in Behçet's disease. | Q36443513 | ||
| Biologic therapies for inflammatory eye disease | Q36501675 | ||
| TNFalpha blockade in human diseases: an overview of efficacy and safety | Q36536861 | ||
| Problems encountered during anti-tumour necrosis factor therapy | Q36595821 | ||
| Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study | Q37146227 | ||
| The possible impact of uveitis in blindness: a literature survey | Q37323541 | ||
| Interferons and their potential in the treatment of ocular inflammation | Q37406596 | ||
| Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. | Q37697383 | ||
| Pharmacotherapy of uveitis | Q37724245 | ||
| Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease | Q37961028 | ||
| Ocular manifestations of the autoinflammatory syndromes | Q38038253 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | sensory nervous system | Q11101 |
| eye disease | Q3041498 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 515312 | |
| P577 | publication date | 2013-11-20 | |
| P1433 | published in | Mediators of Inflammation | Q2144494 |
| P1476 | title | Systemic treatments for noninfectious vitreous inflammation | |
| P478 | volume | 2013 |
| Q30278668 | Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics |
| Q38916649 | Minimally invasive microneedles for ocular drug delivery. |
| Q28079572 | Nanomedicine in the application of uveal melanoma |
| Q33820065 | Pharmacokinetics, electrophysiological, and morphological effects of the intravitreal injection of mycophenolic acid in rabbits |
Search more.